Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease IN RESPONSE

被引：1
|
作者：
Schechter, Meir [1 ,2 ,3 ]
Chertow, Glenn M. [4 ,5 ]
Heerspink, Hiddo J. L. [1 ,6 ]
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands
[2] Hadassah Med Ctr, Diabet Unit, Dept Endocrinol & Metab, Jerusalem, Israel
[3] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
[4] Stanford Univ, Dept Med, Sch Med, Stanford, CA USA
[5] Stanford Univ, Dept Epidemiol & Populat Hlth, Sch Med, Stanford, CA USA
[6] George Inst Global Hlth, Sydney, NSW, Australia
来源：
ANNALS OF INTERNAL MEDICINE | 2023年 / 176卷 / 07期
关键词：
D O I：
10.7326/L23-0070
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease
    Patoulias, Dimitrios
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (07)
  • [2] Summary for Patients: Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease
    Schechter, M.
    Jongs, N.
    Chertow, G. M.
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (01) : I19 - I19
  • [3] Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease: A Post Hoc Analysis of DAPA-CKD
    Schechter, Meir
    Jongs, Niels
    Chertow, Glenn M.
    Mosenzon, Ofri
    McMurray, John J., V
    Correa-Rotter, Ricardo
    Rossing, Peter
    Langkilde, Anna Maria
    Sjostrom, C. David
    Toto, Robert D.
    Wheeler, David C.
    Heerspink, Hiddo J. L.
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (01) : 59 - +
  • [4] Dapagliflozin in Patients with Chronic Kidney Disease
    Vogt, Liffert
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (04): : 388 - 389
  • [5] Dapagliflozin in Patients with Chronic Kidney Disease
    Heerspink, Hiddo J. L.
    Stefansson, Bergur V.
    Correa-Rotter, Ricardo
    Chertow, Glenn M.
    Greene, Tom
    Hou, Fan-Fan
    Mann, Johannes F. E.
    McMurray, John J. V.
    Lindberg, Magnus
    Rossing, Peter
    Sjostrom, C. David
    Toto, Roberto D.
    Langkilde, Anna-Maria
    Wheeler, David C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (15): : 1436 - 1446
  • [6] Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease
    Chertow, Glenn M.
    Vart, Priya
    Jongs, Niels
    Toto, Robert D.
    Gorriz, Jose Luis
    Hou, Fan Fan
    McMurray, John J. V.
    Correa-Rotter, Ricardo
    Rossing, Peter
    Sjostrom, C. David
    Stefansson, Bergur V.
    Langkilde, Anna Maria
    Wheeler, David C.
    Heerspink, Hiddo J. L.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (09): : 2352 - 2361
  • [7] Predicting Hospitalizations for Patients With Chronic Kidney Disease
    Karpinski, Steph
    Sibbel, Scott
    Gray, Kathryn
    Walker, Adam G.
    Luo, Jiacong
    Colson, Carey
    Stebbins, Juliana
    Brunelli, Steven M.
    AMERICAN JOURNAL OF MANAGED CARE, 2023, 29 (09): : E262 - E266
  • [8] Dapagliflozin for rheumatic musculoskeletal disease in patients with chronic kidney disease
    Hanaoka, Hironari
    Kikuchi, Jun
    Hiramoto, Kazuoto
    Akiyama, Mitsuhiro
    Saito, Shutaro
    Kondo, Yasushi
    Azegami, Tatsuhiko
    Kaneko, Yuko
    MODERN RHEUMATOLOGY, 2024,
  • [9] Dapagliflozin versus empagliflozin in patients with chronic kidney disease
    Alnsasra, Hilmi
    Tsaban, Gal
    Solomon, Adam
    Khalil, Fouad
    Aboalhasan, Enis
    Azab, Abed N.
    Azuri, Joseph
    Hammerman, Ariel
    Arbel, Ronen
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [10] The effects of dapagliflozin on kidney and cardiovascular outcomes in patients with chronic kidney disease with and without heart failure
    Heerspink, J. L.
    Wheeler, D. C.
    Vart, P.
    Jongs, N.
    Hou, F. F.
    Langkilde, A. M.
    Correa-Rotter, R.
    Rossing, P.
    Sjostrom, C. D.
    Toto, R. D.
    Chertow, G. M.
    Stefansson, B. V.
    McMurray, J. J. V.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2913 - 2913
12345